


Center for Cancer Research Update

Robert H. Wiltrout, Ph.D., Director Lee A. Helman, M.D., SD for Clinical Research

> December 9, 2008 NCAB









Integrate basic, translational, and clinical research to make cancer preventable, curable, or chronically manageable.



CCR Mission: Focused On The Patient

To inform and empower the entire cancer research community by making breakthrough discoveries in basic and clinical cancer research and by developing them into novel therapeutic interventions for adults and children afflicted with cancer or infected with HIV.



CCR Seeks to Achieve Its Mission By:

 Performing rigorous basic scientific research to discover fundamental mechanisms of biology and cancer

- Translating these advances rapidly from the laboratory to the clinic
- Developing innovative technologies that enable more accurate detection, diagnoses, and treatments
- Pioneering novel interventions for underserved patient populations
- Sharing expertise, scientific data and technologies to broaden the impact of our work and enhance the overall productivity of the cancer research community
- Providing a unique environment to cultivate and train future physicianscientists and biomedical researchers

CCR ScientificPresenations to the 148th Meeting of the NCAB

 <u>Dr. Natasha Caplen</u> - Defining the Cancer Genome using RNAi Analysis and Screening

- <u>Dr. Stephan Ambs</u> Application of Genomic Profiling to Identify Factors that contribute to Cancer Health Disparities
- <u>Dr. Terry Van Dyke</u> Cancer Models: From Insight to Improved Care
- <u>Dr. Marston Linehan</u> The Genetic Basis of Kidney Cancer: Opportunity for Targeted Approaches to Therapy



Center for Cancer Research Update – Closed Session

Robert H. Wiltrout, Ph.D.

Director

December 9, 2008 NCAB



 Critical mass of basic and clinical scientists solving complex scientific problems

- Can quickly redeploy resources to address:
 - (a) NCI mission goals-reduce the burden of cancer
 - (b) Urgent public need-response to AIDS epidemic
 - (c) New opportunities-decoding of the human genome
- Access to NIH Clinical Center

Center for Cancer Research: Organization

Center for Cancer Research

Clinical Branches

Basic Laboratories

Cellular Oncology	Populations Genetics	
Cell & Cancer Biology	Immune Cell Biology	
Resistance Mechanisms	Macromolecular Crystallography	
Molecular Pharmacology	Cancer & Inflammation	
Cancer Biology and Genetics	Cell & Developmental Signaling	
Cancer Prevention	Nanobiology	
Genomic Diversity	Basic Research	
Cell Biology	Molecular Biology	
Molecular Pharmacology	Structural Biophysics	
Medicinal Chemistry	Protein Dynamics & Signaling	
Molecular Targets Discovery	Experimental Immunology	
Molecular Cell Biology	Comparative Carcinogenesis	
Cell Regulation & Carcinogenesis	Molecular Immunoregulation	
Experimental Carcinogenesis	Cancer & Development Biology	
Human Carcinogenesis	Mouse Cancer Genetics	
Retroviral Replication	HIV Drug Resistance	
Mammary Biology & Tumorigenesis	Receptor Biology and Gene Expression	
HIV Drug Resistance	Cellular Carcinogen & Tumor Prom	
Gene Regulation & Chromosome Biology Biochemistry & Molecular Biology	Cellular & Molecular Biology	

Center for Cancer Research: Organization

Center for Cancer Research


Clinical Branches

Basic Laboratories

Dermatology	Genetics
Medical Oncology	Neuro-Oncology
Urologic Oncology	Pediatric Oncology
Experimental Transplant. Immunol.	Surgery
Experimental Immunology	Radiation Oncology
Tumor Immunol. & Biology	Radiation Biology
HIV & AIDS Malignancy	Pathology
Metabolism	Molecular Imaging
Biostatistics & Data Mgmt	Vaccine

CCR Labs and Branches Are Woven Together Around Strategic Priorities

- Understand the Cancer Process from Initiation to Metastasis
- Interrogate the Molecular Genetics of Cancer
- Improve Cancer Prevention, Early Detection, and Diagnostic Approaches
- Develop and Validate Novel Molecularly Targeted
 Interventions
- Harness the Immune System to Combat Cancer
- Discover and Develop Approaches to Combat HIV/AIDS and AIDS-associated Malignancies



Centers of Excellence serve as Focal Points for Bench to Bedside Translation


- Centers of Excellence serve to support the IRPs dedication to long-term, high-risk, innovative basic, clinical, and epidemiologic research
 - Immunology Robert Wiltrout, Head
 - Chromosome Biology Gordon Hager, Head
 - HIV/AIDS and Cancer Virology Stuart LeGrice, Head
 - Molecular Oncology Giuseppe Giaccone, Pat Steeg, Head
 - Integrative Biology, Snorri Thorgeirsson, Head

Program/Initiative


• Cancer and Inflammation – Giorgio Trinchieri, Head

Strategies for Programmatic Integration

Translational Infrastructure Is Collaborative



Research Emphasis Today



Commercial Successes in Fighting Cancer and HIV

Vaccines and Therapeutics

2-F-AraA - Fludara (April 18, 1991) Berlex Videx (October 9, 1991) Berlex Lab Hivid (June 19, 1992) BMS Paclitaxel (Dec. 29, 1992) BMS Trimetrexate – Neu Trexin (Dec. 17, 1993) Zenapax (Dec. 10, 1997) Hoffman La Roche Vitravene (Aug. 26, 1998) Isis Pharma Kepivance (Dec. 15, 2004) Amgen Zevalin (Feb. 19, 2002) IDEC Pharma Gardasil (June 8, 2006) Merck Prezista (June 23, 2006) Tibotec Pharma

Diagnostics

Serological Detection of Antibodies to HIV-1 (March 1, 1985) Serologic Detection of Antibodies to HTLV-1 (Nov. 29, 1988) DNA Probe for Breast Cancer Diagnosis (Dec. 11, 1998) Multi-replica Blotting Kit for Proteins

Instrumentation/Devices

Laser Capture Microdissection

Newly Tenured






Jairaj Acharya, MBBS, Ph.D.

Laboratory of Cell and Developmental Signaling

Phospholipid and sphingolipid signaling in Drosophila


Newly Tenured




Javed Khan, M.D.

Pediatric Oncology Branch

Applying high throughput genomics and proteomics to characterize high risk pediatric malignancies, focusing on neuroblastoma.








2.8 Million

Number of CCR PIs: 2000-2009



Rebuilding the Principal Investigator Community – FY2008

Senior Leadership

- Crystal Mackall, Chief, POB
- J. Carl Oberholtzer, Chief, LP
- Kevin Camphausen, Chief, ROB
- R. Andrew Byrd, Acting Director, Molecular Discovery Program
- Robert Yarchoan, Director for the NCI Office of HIV and AIDS Malignancies
- L. Michelle Bennett, Deputy Director CCR

Newly Hired Tenure Tracks

- Itzhak Avital, SB
- Peter Kalab, LCMB
- Udai Kammula, SB
- Yamini Dalal, LRBGE
- Yinling Hu, LEI
- Jing Huang, LCBG
- Jung-Hyun Park, EIB
- Li Yang, LCBG
- Joseph Ziegelbauer, HAMB
- Ola Landgren, MOB
- Mitchell Ho, LMB
- Brian Lewis, MB
- Chris Buck, LOC
- Deb Citrin, ROB
- King Kwong, SB

Open PI Positions (Nov 2008)

 Mouse Cancer Genetics Program: 2 Tenure Track or Tenured Positions

- Laboratory of Human Carcinogenesis: Tenure Track
- Metabolism Branch: 2 Tenure Track positions
- Medical Oncology Branch: Tenure Track in breast cancer
- Laboratory of Biochemistry and Molecular Biology: Tenure Track
- Laboratory of Molecular Biology: Tenure Track
- Chronic Inflammation & Cancer: Tenure Track
- Neuro Oncology Branch: Tenure Track

Major Searches (Nov 2008)

• Stem Cell Program

- 29 applications received
- 15 top candidates reviewed by

Search Committee

- 6 top candidates interviewed

Chemical Biology Laboratory

Ad has been posted

Overwhelmingly positive response from 24 well-qualified applicants, interviews are scheduled with 8 top candidates



Center for Cancer Research Update – Closed Session

Robert H. Wiltrout, Ph.D.

Director

December 9, 2008 NCAB







- The NCI intramural clinical program is the largest cancerfocused clinical research center (CRC) in the world, capable of performing patient-intensive clinical research focused on developing new approaches for prevention, diagnosis, and treatment of cancer.
- The NCI intramural clinical program is an important component of the nation's overall cancer program